Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?

DISCUSSION: While acknowledging that no randomized controlled prospective studies have been yet conducted comparing TCD versus PTCy in haploidentical allo-HCT recipients, there are two advantages that would favor the PTCy, namely ease of application and lower cost. However, emerging data on adverse events associated with PTCy including, but not limited to cardiac associated toxicities or increased incidence of post-allograft infections, and others, are important to recognize.PMID:38597828 | DOI:10.1080/16078454.2024.2326384
Source: Hematology - Category: Hematology Authors: Source Type: research